JP2008518026A - 副腎皮質刺激ホルモンアナログおよびこれに関連する方法 - Google Patents

副腎皮質刺激ホルモンアナログおよびこれに関連する方法 Download PDF

Info

Publication number
JP2008518026A
JP2008518026A JP2007539117A JP2007539117A JP2008518026A JP 2008518026 A JP2008518026 A JP 2008518026A JP 2007539117 A JP2007539117 A JP 2007539117A JP 2007539117 A JP2007539117 A JP 2007539117A JP 2008518026 A JP2008518026 A JP 2008518026A
Authority
JP
Japan
Prior art keywords
acth
amino acid
seq
acth analog
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2007539117A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008518026A5 (enExample
Inventor
ブレナン，マイルズ・ビー
ドアス，ロバート・エム
ハスケル−ルーヴェイノ・キャリー
ホッジシュウェンダー，ユーテ・エイチ
コスタ，ジェシカ・アイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
Original Assignee
University of Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida filed Critical University of Florida
Publication of JP2008518026A publication Critical patent/JP2008518026A/ja
Publication of JP2008518026A5 publication Critical patent/JP2008518026A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/695—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2007539117A 2004-10-27 2005-10-27 副腎皮質刺激ホルモンアナログおよびこれに関連する方法 Ceased JP2008518026A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62243604P 2004-10-27 2004-10-27
PCT/US2005/038789 WO2006052468A2 (en) 2004-10-27 2005-10-27 Adrenocorticotropic hormone analogs and related methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011197386A Division JP2012067099A (ja) 2004-10-27 2011-09-09 副腎皮質刺激ホルモンアナログおよびこれに関連する方法

Publications (2)

Publication Number Publication Date
JP2008518026A true JP2008518026A (ja) 2008-05-29
JP2008518026A5 JP2008518026A5 (enExample) 2008-08-21

Family

ID=36336951

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007539117A Ceased JP2008518026A (ja) 2004-10-27 2005-10-27 副腎皮質刺激ホルモンアナログおよびこれに関連する方法
JP2011197386A Pending JP2012067099A (ja) 2004-10-27 2011-09-09 副腎皮質刺激ホルモンアナログおよびこれに関連する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011197386A Pending JP2012067099A (ja) 2004-10-27 2011-09-09 副腎皮質刺激ホルモンアナログおよびこれに関連する方法

Country Status (13)

Country Link
US (4) US7919577B2 (enExample)
EP (2) EP2446894A3 (enExample)
JP (2) JP2008518026A (enExample)
KR (3) KR101150242B1 (enExample)
CN (2) CN101189022B (enExample)
AU (2) AU2005305157B2 (enExample)
CA (1) CA2584221A1 (enExample)
IL (1) IL182818A0 (enExample)
MX (1) MX2007004676A (enExample)
NZ (1) NZ554559A (enExample)
RU (2) RU2407751C2 (enExample)
SG (1) SG156680A1 (enExample)
WO (1) WO2006052468A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017503185A (ja) * 2013-12-19 2017-01-26 ユニベルシテイト ゲントＵｎｉｖｅｒｓｉｔｅｉｔ Ｇｅｎｔ 慢性ストレスのバイオマーカーとしての魚のうろこにおけるグルココルチコイドの定量化

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005305157B2 (en) 2004-10-27 2011-09-01 Oklahoma Medical Research Foundation Adrenocorticotropic hormone analogs and related methods
US20100204131A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of a peptide as a therapeutic agent
US8524664B2 (en) 2011-06-02 2013-09-03 Colorado Seminary, Which owns and Operates The Univeristy of Denver Methods of treating overproduction of cortisol using ACTH antagonist peptides
WO2014168721A2 (en) 2013-04-12 2014-10-16 Tufts Medical Center Methods and systems for designing and/or characterizing soluble lipidated ligand agents
CN104277105B (zh) * 2013-07-12 2017-12-12 国家纳米科学中心 抑制β淀粉样蛋白聚集和毒性的多肽抑制剂及其应用
CN103724427B (zh) * 2013-11-29 2016-09-28 青岛康原药业有限公司 一种精制促皮质素的方法
CA3265373A1 (en) 2014-02-20 2025-10-30 H. Lundbeck A/S Anti-acth antibodies and use thereof
EP3233916A4 (en) 2014-12-19 2018-06-06 Alder Biopharmaceuticals, Inc. Humanized anti-acth antibodies and use thereof
CN104530219A (zh) * 2014-12-23 2015-04-22 青岛康原药业有限公司 一种精制促皮质素的方法
CA2983030A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
ES2805037T3 (es) 2016-01-22 2021-02-10 Tufts Medical Ct Inc Compuestos y métodos para tratar la inflamación
CN105669856A (zh) * 2016-02-13 2016-06-15 王大勇 一种基因重组长效人促肾上腺皮质激素及其制备方法
PE20181583A1 (es) 2016-03-01 2018-10-04 Immatics Biotechnologies Gmbh Peptido recombinante derivado de la proteina duoxa2
SG10202109691UA (en) 2016-04-15 2021-10-28 Alder Biopharmaceuticals Inc Anti-pacap antibodies and uses thereof
CN106478771A (zh) * 2016-10-09 2017-03-08 李世军 一种氨基酸神经四肽的合成方法
WO2018118115A1 (en) * 2016-12-19 2018-06-28 Eton Pharmaceuticals, Inc. Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof
US11338018B2 (en) 2016-12-19 2022-05-24 Harrow Ip, Llc Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof
CN110698557B (zh) * 2019-11-06 2021-06-18 郑州伊美诺生物技术有限公司 Acth突变体、重组蛋白及其应用，以及含有该acth重组蛋白的试剂盒
CN116761809A (zh) * 2021-04-12 2023-09-15 南京汉欣医药科技有限公司 一种高纯的人促肾上腺皮质激素或其类似物及其规模化制备方法
US12433936B2 (en) 2021-04-12 2025-10-07 Nanjing Hanxin Pharmaceutical Technology Co., Ltd. High-purity adrenocorticotropic hormone analogue and a large-scale preparation method thereof
CN120420414A (zh) * 2024-02-04 2025-08-05 南京汉欣医药科技有限公司 含有人工合成的促皮质素类似物的组合物、其制备方法以及其用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6A (en) * 1836-08-10 Thomas Blanchard Machine for forming end pieces of plank blocks for ships
US4415546A (en) 1981-05-12 1983-11-15 Janakiraman Ramachandran Biologically active analogs of ACTH and radioimmuno assay therefor
US4457864A (en) 1981-10-23 1984-07-03 University Patents, Inc. Synthetic analogues of α-melanotropin
US4485039A (en) 1982-06-11 1984-11-27 University Patents, Inc. Synthetic analogues of α-melanotropin
US4649191A (en) 1984-05-10 1987-03-10 Gibson-Stephens Neuropharmaceuticals, Inc. Conformationally constrained alpha-melanotropin analogs with specific central nervous system activity
DE3783541T2 (de) 1986-02-03 1993-06-17 University Patents Inc Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen.
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5049547A (en) 1988-02-11 1991-09-17 University Patents, Inc. Composition for stimulating integumental melanocytes
US4948580A (en) 1988-12-08 1990-08-14 E. R. Squibb & Sons, Inc. Muco-bioadhesive composition
JPH02258718A (ja) 1989-03-31 1990-10-19 Nippon Kayaku Co Ltd ペースト状基剤及び製剤
US5189018A (en) 1991-08-19 1993-02-23 Wayne State University Method for reduction of central nervous system (cns) edema resulting from head and spinal cord trauma
JPH08503950A (ja) 1992-12-02 1996-04-30 アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド 徐放性成長ホルモン含有マイクロスフェア
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
ES2154673T3 (es) 1993-01-29 2001-04-16 Aradigm Corp Suministro intrapulmonar de hormonas.
US5554380A (en) 1994-08-04 1996-09-10 Kv Pharmaceutical Company Bioadhesive pharmaceutical delivery system
EP1002529A1 (en) 1994-09-09 2000-05-24 Takeda Chemical Industries, Ltd. Sustained-release preparation containing a metal salt of a peptide
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
SK281571B6 (sk) 1995-06-07 2001-05-10 Alkermes Controlled Therapeutics, Inc. Prostriedok na trvalé uvoľňovanie ľudského rastového hormónu
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US6346390B1 (en) * 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
GB9606016D0 (en) 1996-03-22 1996-05-22 Smithkline Beecham Plc Novel use
IE960308A1 (en) 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US5942243A (en) 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
AR012448A1 (es) 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
US6056954A (en) 1997-10-31 2000-05-02 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses
WO2000000507A1 (en) 1998-06-26 2000-01-06 Pfizer Products Inc. Improved process for preparing schiff base adducts of amines with o-hydroxy aldehydes and compositions of matter based thereon
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
WO2000074679A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
IES990700A2 (en) 1999-08-18 2001-08-22 Kinerton Ltd Process to make a sustained release formulation
US6056955A (en) 1999-09-14 2000-05-02 Fischetti; Vincent Topical treatment of streptococcal infections
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
WO2001080830A2 (en) 2000-04-21 2001-11-01 Advanced Research And Technology Institute, Inc. Pharmacotherapeutic process and composition for central nervous system disorders
US6689938B2 (en) 2000-09-13 2004-02-10 Oklajoma Medical Research Foundation Method for treatment of insulin resistance in obesity and diabetes
EP1334114A2 (en) 2000-10-25 2003-08-13 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
US20050049549A1 (en) 2003-08-04 2005-03-03 Wong Patrick S.L. Method and device for enhancing transdermal agent flux
WO2005044142A2 (en) 2003-11-10 2005-05-19 Angiotech International Ag Intravascular devices and fibrosis-inducing agents
US20050147581A1 (en) 2003-11-19 2005-07-07 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes having improved stability and therapeutic use of the same
AU2005305157B2 (en) 2004-10-27 2011-09-01 Oklahoma Medical Research Foundation Adrenocorticotropic hormone analogs and related methods

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017503185A (ja) * 2013-12-19 2017-01-26 ユニベルシテイト ゲントＵｎｉｖｅｒｓｉｔｅｉｔ Ｇｅｎｔ 慢性ストレスのバイオマーカーとしての魚のうろこにおけるグルココルチコイドの定量化

Also Published As

Publication number Publication date
US20060128620A1 (en) 2006-06-15
WO2006052468A2 (en) 2006-05-18
CN101189022A (zh) 2008-05-28
EP1814574A2 (en) 2007-08-08
US20070197774A1 (en) 2007-08-23
KR101242543B1 (ko) 2013-03-22
MX2007004676A (es) 2007-11-14
US7264314B2 (en) 2007-09-04
CA2584221A1 (en) 2006-05-18
IL182818A0 (en) 2007-08-19
KR20070112761A (ko) 2007-11-27
RU2407751C2 (ru) 2010-12-27
US20100260681A1 (en) 2010-10-14
US7919577B2 (en) 2011-04-05
KR101150242B1 (ko) 2012-06-13
KR20120050440A (ko) 2012-05-18
RU2010135499A (ru) 2012-02-27
AU2005305157A1 (en) 2006-05-18
JP2012067099A (ja) 2012-04-05
AU2011201914A1 (en) 2011-05-19
EP2446894A2 (en) 2012-05-02
EP1814574A4 (en) 2009-08-05
US20080207518A1 (en) 2008-08-28
SG156680A1 (en) 2009-11-26
EP2446894A3 (en) 2013-02-20
KR20100102752A (ko) 2010-09-24
WO2006052468A3 (en) 2007-01-11
AU2005305157B2 (en) 2011-09-01
RU2007119580A (ru) 2008-12-10
CN101189022B (zh) 2012-02-29
CN101947310A (zh) 2011-01-19
KR101058467B1 (ko) 2011-08-24
NZ554559A (en) 2010-05-28

Similar Documents

Publication Publication Date Title
JP2012067099A (ja) 副腎皮質刺激ホルモンアナログおよびこれに関連する方法
EVERETT The control of the secretion of prolactin
Erspamer et al. The brain-gut-skin triangle: new peptides
RU2502519C2 (ru) Терапевтическое средство для лечения ринита
Park et al. The gubernaculum shows rhythmic contractility and active movement during testicular descent
JP2009280598A (ja) 胃腸管上部の機能を強化する方法
JP2011256178A (ja) 非閉経女性における卵胞貯蔵を調節するのに意図した医薬を製造するのにソマトスタチン又はその同族体の１つの使用
HK1043059A1 (en) Tumor necrosis factor antagonists and their use in endometriosis
JPH05507493A (ja) 哺乳動物の性腺刺激ホルモンレベルを調節するためのＧｎＲＨ拮抗薬とＧｎＲＨによる組合せ治療
TW200422042A (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
JP2005501919A (ja) 制御下の過排卵刺激におけるｈＣＧ及びＬＨの使用
HK1148194A (en) Adrenocorticotropic hormone analogs and related methods
JP2000513749A (ja) Ｆｓｈ放出ホルモン
US6407205B1 (en) FSH-releasing peptides
JP2024020797A (ja) 筋萎縮の治療剤
Raja et al. Influence of TNF alpha on testosterone induced cardiac effects in isolated frog heart model.
HK1082690B (en) Tumor necrosis factor antagonists and their use in endometriosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080605

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110309

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110606

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110909

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110913

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120726

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20141120